Trial
NCT03422627
Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chronic Graft Versus Host Disease
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Amgen
Collaborators
—
Condition
Chronic Graft Versus Host Disease cGVHD
Intervention
Efavaleukin Alfa
Why stopped
Sponsor Decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-11-22